Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease

(2023) Mary E. Rinella et al.   HEPATOLOGY

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

(2023) Zobair M. Younossi et al.   HEPATOLOGY

A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials

(2023) Raluca Pais et al.   JOURNAL OF HEPATOLOGY

Placebo effect on progression and regression in NASH : Evidence from a meta‐analysis

(2022) Cheng Han Ng et al.   HEPATOLOGY

Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss

(2022) Sjaak Pouwels et al.   BMC Endocrine Disorders

Pegozafermin improved liver histology, liver-related non-invasive tests (NITs) and metabolic profiles in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)

(2022) Rohit Loomba et al.   JOURNAL OF HEPATOLOGY

The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis

(2022) Kiarash Riazi et al.   Lancet Gastroenterology & Hepatology

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study

(2022) Rohit Loomba et al.   Lancet Gastroenterology & Hepatology

Mechanisms and disease consequences of nonalcoholic fatty liver disease

(2021) Rohit Loomba et al.   CELL

Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort

(2021) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in obese adults with modest hypertriglyceridemia

(2021) Daniel J Rader et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

(2021) Sven M. Francque et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis

(2021) Rohit Loomba et al.   GASTROENTEROLOGY

Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations from the Liver Forum

(2020) Oliver Glass et al.   JOURNAL OF HEPATOLOGY

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

(2020) Stephen A. Harrison et al.   GASTROENTEROLOGY

LBP-29-BIO89-100, a novel PEG-FGF21 analogue, is efficacious following weekly and every 2-week subcutaneous dosing in spontaneous diabetic cynomolgus monkeys

(2019) Moti Rosenstock et al.   JOURNAL OF HEPATOLOGY

Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH

(2019) Rohit Loomba et al.   HEPATOLOGY

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

(2019) Paul J. Pockros et al.   LIVER INTERNATIONAL

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

(2017) Chris Estes et al.   HEPATOLOGY

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

(2016) Saswata Talukdar et al.   Cell Metabolism

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status

(2012) Yenna Lee et al.   CLINICAL ENDOCRINOLOGY